The manager of a table-topping biotechnology trust has said careful use of the closed-ended structure has enabled him to outperform, including holding half of his assets in just five stocks.
Daniel Koller, who leads the management team for the BB Biotech trust, said that the independence of the closed-ended structure allowed him to take significant positions of 10% or more in selected stocks....
Working in London and Geneva
Staunch value investor
Effective 24 September
Latest edition of the print magazine online
Four-part Big Question special